Our findings demonstrated that CHD4 exhibits oncogenic properties, as evidenced by its overexpression up-regulating ERα through two pathways, increasing the mRNA of ERα and decreasing its protein ubiquitin-dependent degradation in ERα-positive breast cancer. The gene discussed is ESR1; the disease is breast cancer.